Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
65
days
Antibody–drug conjugates combined with immune checkpoint inhibitors in cancer: mechanisms, clinical evidence, and translational challenges
Authors
Yangchun Du; Zhaozhong Tu; Min Ling; Peng Luo; Lijun Li; Yizhao Luo; Zhiwei MaShow moreShow less
Affiliations
1. Department of Organ Transplantation, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, China; 2. Center of Anesthesiology and Operating Rooms, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, China; 3. Department of Oncology, Southern Medical University, Zhujiang Hospital, Guangzhou, China; 4. Shantou University Medical College, Shantou, China; 5. Department of Urology, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Sichuan Provincial People’s Hospital, Chengdu, ChinaShow moreShow less
111
days
Lactate metabolism and epigenetic reprogramming in cancer: beyond energy metabolism to chromatin dynamics
Authors
Sitong Li; Jintian Zhang; Feng Zhao; Changjing Cai; Namei Li; Kai LiuShow moreShow less
Affiliations
1. Department of Oncology, Xiangya Hospital, Central South University, Changsha, China; 2. Xiangya School of Medicine, Central South University, Changsha, China; 3. Department of Cardiology, Beijing Hospital, Peking Union Medical College Hospital, Beijing, China; 4. Department of Neurology, Peking University First Hospital, Beijing, China; 5. National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, China; 6. Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha, China; 7. Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China; 8. Transplantation Center, The Third Xiangya Hospital, Central South University, Changsha, China; 9. NHC key laboratory of translational research on transplantation medicine, Changsha, ChinaShow moreShow less
67
days
Lactate and lactylation in cancer: mechanistic insights and therapeutic implications
Authors
Ting Liu; Chen Huang; Chenliang Zhang; Yuyuan Xiong; Xudong Wang; Zhenyu DingShow moreShow less
Affiliations
1. Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 2. Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China; 3. Division of Abdominal Tumor Multimodality Treatment, Cancer Center and Laboratory of Abdominal Tumor Immunology and Microenvironment, West China Hospital, Sichuan University, Chengdu, China; 4. Department of Medical Engineering Technology, West China Hospital, Sichuan University, Chengdu, China; 5. Department of Orthopedics, Junlian County People’s Hospital, Sichuan, ChinaShow moreShow less
140
days
From molecular bridges to therapeutic targets: the pivotal role of liquid-liquid phase separation in tumors and new frontiers in targeted therapy
Authors
Yuxiang Chen; Yining Sun; Feifan Chen; Binyang Luo; Zhu Wang; Yuzhi Liu; Kai Deng; Jinlin YangShow moreShow less
Affiliations
1. Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China; 2. Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital of Sichuan University, Chengdu, ChinaShow moreShow less
177
days
The evolution of “magic bullets”: precision guidance, clinical challenges, and efficacy enhancement of antibody-drug conjugates in solid tumors
Authors
Ying Li; Junfeng Zhao; Jiaxuan Chen; Yifei Yan; Chen Zhou; Wenjie Chen; Yali Xu; Chao Tu; Yintao LiShow moreShow less
Affiliations
1. Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 2. Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 3. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 4. Department of Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; 5. Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China; 6. Department of Pathology, Shandong Provincial Hospital Affiliated with Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan, China; 7. Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China; 8. Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China; 9. Hunan Engineering Research Center of AI Medical Equipment, The Second Xiangya Hospital of Central South University, Changsha, China; 10. Department of Medical Oncology, Peking University First Hospital, Peking University, Beijing, ChinaShow moreShow less
195
days
Increasing cancer stemness drives prostate cancer progression, plasticity, therapy resistance and poor patient survival
Authors
Xiaozhuo Liu; Anmbreen Jamroze; Eduardo Cortes; Yibing Ji; Kathy Zhao; Faming Zhao; Julian Ho; Yang Liu; Elai Davicioni; Shan Wu; Wen Jess Li; Felix Y. Feng; Joshi J. Alumkal; Daniel E. Spratt; Christopher J. Sweeney; Han Yu; Qiang Hu; Cheng Zou; Dingxiao Zhang; Kevin Lin; Yue Lu; Gurkamal Chatta; Kent L. Nastiuk; David W. Goodrich; Kiera Rycaj; Jason S. Kirk; Igor Puzanov; Zheng Xia; Song Liu; Jianmin Wang; Dean G. TangShow moreShow less
Affiliations
1. Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 2. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 3. Department of Biostatistics, University at Buffalo, Buffalo, USA; 4. Veracyte Inc, San Diego, USA; 5. Department of Biomedical Engineering, The University of Texas at Austin, Austin, USA; 6. Experimental Therapeutics Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, USA; 7. Department of Radiation Oncology, University of California, San Francisco, USA; 8. Department of Internal Medicine, Department of Hematology and Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, USA; 9. University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, USA; 10. South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia; 11. School of Biomedical Sciences, Hunan University, Changsha, China; 12. Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, Houston, USA; 13. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, USA; 14. Department of Cancer Genetics, Roswell Park Comprehensive Cancer Center, Buffalo, USAShow moreShow less
FAQ
How long does Molecular Cancer take to review a manuscript?
As of 2026-11-18, CrushSCI has 20 complete review records for Molecular Cancer. The fastest paper went from submission to acceptance in 36 days (Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation, received 2026-04-13, accepted 2026-05-19); the slowest took 230 days. The average is 115.1 days and the median is 97.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
